Prescription medicine
Bevacizumab-maly Brand names: Alymsys
Bevacizumab-maly (Alymsys) is a prescription medicine with an FDA approval on record since 2022. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the bevacizumab-maly FDA label on DailyMed (effective January 27, 2026, Valorum Biologics, LLC); the BLA 761231 record on Drugs@FDA; every bevacizumab-maly label on DailyMed.
Highlights of the record
FDA label of January 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageAlymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
Forms and strengths
- 100 mg/4ml
- 400 mg/16ml
Injection (solution).
On the market
- Earliest approval on file
- April 13, 2022 Alymsys, Amneal Pharms Llc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 191 through July 30, 2026
What is bevacizumab-maly used for?
From the label: indications and usageAlymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. (1.1) Limitations of Use: Alymsys is not indicated for adjuvant treatment of colon cancer. […]
Conditions named in the indications of bevacizumab-maly's FDA labels, with every medicine labeled for each:
From other bevacizumab-maly labelsColorectal cancer: Metastatic Colorectal Cancer Alymsys, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer (mCRC).
Lung cancer: First-Line Non-Squamous Non–Small Cell Lung Cancer Alymsys, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous …
FDA pharmacologic class: Vascular Endothelial Growth Factor Inhibitor.
Source: FDA drug label (ALYMSYS), BLA761231 (Amneal Pharms Llc), as published by Valorum Biologics, LLC, effective January 27, 2026 (SPL set 42b4f96e-1f70-2126-e063-6294a90a93e3), via openFDA; the full label on DailyMed
Is there a generic for bevacizumab-maly (Alymsys)?
No generic bevacizumab-maly is approved (Drugs@FDA, October 8, 2026).
- 2022 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the bevacizumab-maly label say about other medicines?
The bevacizumab-maly label names 5 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Bevacizumab | drug interactions | DRUG INTERACTIONS Effects of Alymsys on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; … |
| Carboplatin | drug interactions | DRUG INTERACTIONS Effects of Alymsys on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; … |
| Epinephrine | warnings and precautions | Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). |
| Irinotecan | drug interactions | DRUG INTERACTIONS Effects of Alymsys on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; … |
| Paclitaxel | drug interactions | DRUG INTERACTIONS Effects of Alymsys on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; … |
Source: FDA drug label (ALYMSYS), BLA761231 (Amneal Pharms Llc), as published by Valorum Biologics, LLC, effective January 27, 2026 (SPL set 42b4f96e-1f70-2126-e063-6294a90a93e3), via openFDA; the full label on DailyMed
What do FAERS reports show for bevacizumab-maly?
The FDA Adverse Event Reporting System holds 191 reports that list bevacizumab-maly among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 36 are coded as a death and 53 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as bevacizumab-maly?
12 other medicines are given the same way (intravenous) and in the same FDA class as bevacizumab-maly or labeled mainly for the same use (colorectal cancer), the same class first. Colorectal cancer lists all 23 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Bevacizumab | Lung cancer, Colorectal cancer | none listed | n/a | No current entry |
| Aflibercept | Colorectal cancer | none listed | n/a | No current entry |
| Oxaliplatin | Colorectal cancer | 17 labelers | n/a | A presentation being discontinued |
| Fluorouracil | Colorectal cancer | 12 labelers | n/a | No current entry |
| Irinotecan | Colorectal cancer | 12 labelers | n/a | A presentation being discontinued |
| Levoleucovorin | Colorectal cancer | 8 labelers | n/a | No current entry |
| Nivolumab | Lung cancer, Colorectal cancer | none listed | n/a | No current entry |
| Ipilimumab | Lung cancer, Colorectal cancer | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as bevacizumab-maly
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to bevacizumab-maly
- 12 medicines for the same use
- Other vascular endothelial growth factor inhibitors
- the pharmacologic class, with prices and generics
- Bevacizumab-maly side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other